Piper Jaffray maintains their Buy rating and $61 price target on Amylin Pharmaceuticals (NASDAQ: AMLN) after the company's pancreatitis update ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE